CRSP N Stock Overview
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
CRISPR Therapeutics AG Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$960.00 |
52 Week High | US$1,481.65 |
52 Week Low | US$871.00 |
Beta | 1.74 |
1 Month Change | -24.41% |
3 Month Change | -11.11% |
1 Year Change | 1.59% |
3 Year Change | -64.77% |
5 Year Change | n/a |
Change since IPO | -58.09% |
Recent News & Updates
Recent updates
Shareholder Returns
CRSP N | MX Biotechs | MX Market | |
---|---|---|---|
7D | -8.6% | 0% | 0% |
1Y | 1.6% | 0% | 0% |
Return vs Industry: CRSP N exceeded the MX Biotechs industry which returned -9% over the past year.
Return vs Market: CRSP N matched the MX Market which returned 1.4% over the past year.
Price Volatility
CRSP N volatility | |
---|---|
CRSP N Average Weekly Movement | n/a |
Biotechs Industry Average Movement | 0% |
Market Average Movement | 0% |
10% most volatile stocks in MX Market | 0% |
10% least volatile stocks in MX Market | 0% |
Stable Share Price: CRSP N's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine CRSP N's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2013 | 407 | Sam Kulkarni | www.crisprtx.com |
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, immune-oncology and autoimmune, in vivo, and type 1 diabetes.
CRISPR Therapeutics AG Fundamentals Summary
CRSP N fundamental statistics | |
---|---|
Market cap | Mex$79.99b |
Earnings (TTM) | -Mex$2.63b |
Revenue (TTM) | Mex$6.35b |
12.6x
P/S Ratio-30.4x
P/E RatioIs CRSP N overvalued?
See Fair Value and valuation analysisEarnings & Revenue
CRSP N income statement (TTM) | |
---|---|
Revenue | US$371.21m |
Cost of Revenue | US$517.58m |
Gross Profit | -US$146.38m |
Other Expenses | US$7.23m |
Earnings | -US$153.61m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -1.81 |
Gross Margin | -39.43% |
Net Profit Margin | -41.38% |
Debt/Equity Ratio | 0% |
How did CRSP N perform over the long term?
See historical performance and comparison